scholarly article | Q13442814 |
review article | Q7318358 |
P356 | DOI | 10.1016/S0002-9149(97)00575-4 |
P698 | PubMed publication ID | 9291244 |
P2093 | author name string | R A Harrington | |
P2860 | cites work | Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration | Q29619529 |
Clinical pharmacology of eptifibatide | Q33500262 | ||
Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study | Q34247562 | ||
Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology | Q34308581 | ||
Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty | Q34336722 | ||
Blockade of Platelet GPIIb/IIIa Receptors as an Antithrombotic Strategy | Q40430655 | ||
Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine | Q40518648 | ||
Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor | Q40966386 | ||
Antiplatelet and anticoagulant use after myocardial infarction | Q41046059 | ||
Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial | Q49173352 | ||
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. | Q50994986 | ||
Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients | Q54066813 | ||
A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes | Q56945341 | ||
Late assessment of thrombolytic efficacy (LATE) study: Prognosis in patients with non-Q wave myocardial infarction | Q56945424 | ||
Pathophysiology and management of unstable angina | Q69384213 | ||
Unstable angina. A classification | Q69664288 | ||
Aspirin, heparin, or both to treat acute unstable angina | Q70216460 | ||
Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death | Q71306624 | ||
One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non- | Q71827444 | ||
Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia | Q72344109 | ||
P433 | issue | 4A | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | unstable angina | Q2032041 |
P304 | page(s) | 34B-38B | |
P577 | publication date | 1997-08-01 | |
P1433 | published in | American Journal of Cardiology | Q2208417 |
P1476 | title | Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy | |
P478 | volume | 80 |
Q61806944 | A Review of Antiplatelet Activity of Traditional Medicinal Herbs on Integrative Medicine Studies |
Q48028091 | Acute coronary syndromes: 2. Antiplatelet agents |
Q45937919 | Antiplatelet therapy. Aspirin, ticlopidine/clopidogrel, and anti-integrin agents. |
Q43435430 | Association of the PURSUIT risk score with predischarge ejection fraction, angiographic severity of coronary artery disease, and mortality in a nonselected, community-based population with non-ST-elevation acute myocardial infarction. |
Q33500262 | Clinical pharmacology of eptifibatide |
Q28193162 | Clinical trials of glycoprotein IIb/IIIa inhibitors |
Q28177271 | Clinical use of new antithrombotic therapies for medical management of acute coronary syndromes |
Q33781957 | Development of eptifibatide |
Q43571946 | Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study |
Q33391279 | Eptifibatide: The evidence for its role in the management of acute coronary syndromes |
Q33922853 | Fibrinogen receptor antagonists: design and clinical applications |
Q37011736 | Integrin αIIbβ3: from discovery to efficacious therapeutic target |
Q33635835 | Interventional therapy is the best approach for acute coronary syndromes |
Q30305538 | Management of Acute Ischemic Coronary Syndromes: The Present and Future |
Q34053362 | Management of patients with non-ST-segment elevation acute coronary syndromes: insights from the PURSUIT trial. |
Q33655209 | New thrombolytics, anticoagulants, and platelet antagonists: the future of clinical practice |
Q35663845 | Perspectives on the future of platelet glycoprotein IIb/IIIa blockade therapy |
Q89169483 | Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases |
Q24202522 | Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes |
Q24202999 | Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes |
Q24235385 | Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes |
Q28191096 | Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction |
Q32076709 | Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy |
Q45295347 | Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet |
Q38009702 | Risk stratification and timing of revascularization: which patients benefit from early versus later revascularization? |
Q34746674 | The development of interventional cardiology |
Q33689211 | The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes |
Q28196102 | Using a Systemwide Care Path to Enhance Compliance with Guidelines for Acute Myocardial Infarction |